Alluvi, previously BI 4744, represents a notable breakthrough in weight management care. This dual agonist targeting both GLP-1 and GIP sites demonstrates impressive results in research trials, possibly outperforming https://wearethelist.com/story24368056/alluvi-a-comprehensive-dive-into-the-retatrutide-s-possibilities